Navigation Links
INBRACED awards $400,000 grant to launch an international neuroblastoma clinical trial
Date:5/22/2014

Solving Kids' Cancer, the Neuroblastoma Children's Cancer Alliance (NCCA UK), and Joining Against Cancer in Kids (J-A-C-K) awarded its first grant through their INBRACED (International Neuroblastoma Research and Collaboration for Effective Delivery) initiative, which aims to improve access of promising clinical trials for children with high-risk neuroblastoma in North America, the UK and in Europe. The grant amount of $400,000 will create a new immunotherapy treatment option in the U.S., UK, and in Spain, for children with relapsed or refractory disease. The international phase I clinical trial will use a vaccine that targets the GD2 and GD3 antigens, which has already shown promising results in children with neuroblastoma in the U.S.

The low-toxicity vaccine was developed by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City, which is participating in the trial alongside Bristol Children's Hospital in the UK, and the Hospital Sant Joan de Du Barcelona, in Spain. The vaccine utilizes a child's own immune system to help the body recognize and destroy cancer cells that express the two antigens most commonly found on the surface of neuroblastoma cellsGD2 and GD3, potentially promoting long-term remissions in these children. A phase I trial with this same vaccine was recently completed at MSKCC with 15 patients and demonstrated very promising results; the results were published in the March 2014 issue of Clinical Cancer Research.

This is the first international clinical trial for children with cancer that has been initiated and sponsored solely by pediatric cancer nonprofits. "The success of this new partnership lies in the amazing determination of UK and U.S. charities, parents, research institutions, doctors and pharmaceutical organization to help more children survive," said Bettina Bungay-Balway, Chief Executive of the London-based NCCA UK.

"We truly hope this will speed the exploration and evolution of potential therapies for the children and their families blighted by neuroblastoma," said Richard Brown, Chair at J-A-C-K.

Neuroblastoma is a cancer of the sympathetic nervous system that most commonly occurs in infants and children under five. The cancer is usually discovered after it has spread. Half of all children diagnosed have high-risk neuroblastoma, one of the most aggressively treated of all childhood cancers. Unfortunately, even after intense chemotherapy and radiation, the cancer often returns in many children. Immunotherapy clinical trials have shown dramatic results in adults and in children with leukemia in the U.S., but such novel options are limited in the UK and in Europe.

"All families should have access to novel experimental treatment options and not have to travel across continents or go in debt for a chance to treat their child," said Scott Kennedy, the Executive Director of Solving Kids' Cancer. "Our goal as part of INBRACED is to have the leading cancer centers in the U.S., U.K., and Europe collaborate on clinical trials to develop treatments with the highest potential for cures."


'/>"/>

Contact: Jenny
jenny@solvingkidscancer.org
212-588-6625
Solving Kids' Cancer
Source:Eurekalert

Related medicine news :

1. NIH awards $20 million over 5 years to train next generation of global health researchers
2. AFAR announces the 2012 Hartford Centers of Excellence in Geriatric Medicine awards
3. Washingtons Life Sciences Discovery Fund awards commercialization grants
4. Awards celebrate clinical research that can improve health and alleviate suffering
5. Presidential Recognition Awards presented during the 2012 AIUM Annual Convention
6. Awards to 5 IU School of Medicine physicians address critical need for geriatricians
7. Biomedical researchers receive Hartwell Foundation awards
8. Lawson researcher receives 1 of first-ever Pfizer Psychiatry Research Awards
9. AGA announces prestigious awards recognition recipients
10. US Army internal medicine residents receive awards from American College of Physicians
11. Outstanding high school students receive awards to stimulate research interest in digestive diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... in the greater Dallas, Miami, and Raleigh regions, is organizing an extended charity ... a rare and deadly chromosome abnormality. , After struggling since birth with several ...
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association ... standards of excellence for the field of eating disorders, announces the opening of ... 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. , ...
(Date:10/13/2017)... Calif. (PRWEB) , ... October 13, 2017 , ... Many ... dementia. However, many long-term care insurance companies have a waiver for care if the ... 90-day elimination period, when the family pays for care, is often waived, so the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented ... the lowdown on sciatica in a new episode of "Success Files," which is ... events and innovation and investigates each subject in-depth with passion and integrity. , ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017 ... mobile health and big data solutions, today announced that its MyDario product ... check your local TV listings for when The Dr. Oz Show airs ... The ... this month. ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
(Date:9/19/2017)... 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, ... three leadership team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has ...
Breaking Medicine Technology: